Neuroendocrine dysfunction in galactorrhea-amenorrhea after oral contraceptive use.
Nonpuerperal  alactorrhea and amenorrhea have been reported following the use of oral contraceptives. Treatment of this condition with ergot alkaloids has proved to be of great therapeutic value. Pretreatment plasma hLH and hFSH concentrations in 13 women with postqill galactorrhea-amenorrhea (PPGA) were 6.6 plus or minus 0.6 (SE.) and 5.0 plus or minus 0.8 mlU/ml, respectively. The mean prolactin concentration was 80.7 plus or minus 13.2 ng/ml. After complete evaluation in which diagnostic evidence of pituitary tumor was absent, the patients were treated with ergocryptine (CB-154). The mean hPRL concentration at 14 days of therapy was 7.8 p;us or minus 1.9 ng/ml. Cyclic gonadotropin secretion resumed in all but one instance; ovulation was confirmed on the basis of a biphasic temperature chart and in 5 cases, endometrial biopsy. Measurement of serum dopamine-beta-hydroxylase (DBH) activity indicated a significant decline at the end of 8 weeks of CB-154 therapy. The fall in hPRL was not necessarily associated with a fall in DBH. The majority of women in this study exhibited a consistent personality suggesting varying degrees of anxiety unrelated to the PPGA  and usually antedating the use of oral contraceptives. PPGA was found in women without hyperprolactinemia, but altered hPRL secretion was evident in all instances. The data suggest that the disorder of cyclic gonadotropin secretion is related to altered hPRL secretion, but the mechanism is possibly related to a catecholamine abnormality. The data support the presence of an inherent cyclic mechanism for the secretion of gonadotropins. CB-154 therapy does not affect conception, and no teratogenic effects were observed in 2 infants born to  women who had received CB-154 during the first 40 days of gestation.
D000028:Abortion, Induced; D000022:Abortion, Spontaneous; D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D003276:Contraceptives, Oral / Q000009:adverse effects*; D004299:Dopamine beta-Hydroxylase / Q000097:blood; D004876:Ergot Alkaloids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005687:Galactorrhea / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D007775:Lactation Disorders / Q000139:chemically induced*; D007986:Luteinizing Hormone / Q000097:blood; D008598:Menstruation; D010060:Ovulation; D010901:Pituitary Function Tests; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D011584:Psychology
D003276:Contraceptives, Oral; D004876:Ergot Alkaloids; D011374:Progesterone; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D004299:Dopamine beta-Hydroxylase